Dan Markingson and the University of Minnesota
Nonumes probatus indoctum cum no, cum te quis liber graecis. Sint paulo choro at sit, vim constituto omittantur id. Sint phaedrum adipiscing et sed. Eum et saperet concludaturque, ex per diam aperiam fuisset, te quo novum nonumes singulis. Mei ei amet prodesset, eum mazim numquam appetere an. __________________________
U doctor scrutinized over drug research
Questions raised after positive review of drug conflicts with maker’s
A top University of Minnesota psychiatrist’s ties to a drug maker have come under scrutiny because he reported that the company’s blockbuster antipsychotic, Seroquel, was significantly superior to other drugs — despite evidence to the contrary.
The disconnect between the company’s private findings in March 2000 and the psychiatrist’s optimistic report to the American Psychiatric Association in May 2000 are further evidence to critics that the drug industry can shape, revise or even conceal negative research.
It also feeds concerns that drug companies are paying noted doctors such as Schulz, the U’s chair of psychiatry, for research results that advance their marketing agendas. Schulz has received $112,000 in consulting fees and university grants from 2002 through 2007 from AstraZeneca, according to state records, and nearly $450,000 from rival drug maker Eli Lilly.